PUBLICAÇÕES científicas

/cun/pt/investigacion/publicaciones-cientificas/areaMain/02
  • Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer

    Duruisseaux M (1), Martínez-Cardús A (2), Calleja-Cervantes ME (2), Moran S (2), Castro de Moura M (2), Davalos V (2), Piñeyro D (2), Sanchez-Cespedes M (2), Girard N (3), Brevet M (4), Giroux-Leprieur E (5), Dumenil C (6), Pradotto M (7), Bironzo P (7), Capelletto E (7), Novello S (7), Cortot A (8), Copin MC (9), Karachaliou N (10), Gonzalez-Cao M (11), Peralta S (12), Montuenga LM (13), Gil-Bazo I (14), Baraibar I (15), Lozano MD (16), Varela M (17), Ruffinelli JC (18), Palmero R (18), Nadal E (18), Moran T (19), Perez L (20), Ramos I (21), Xiao Q (22), Fernandez AF (23), Fraga MF (24), Gut M 25, Gut I (25), Teixidó C (26), Vilariño N (27), Prat A (27), Reguart N (27), Benito A (28), Garrido P (29), Barragan I (30), Emile JF (31), Rosell R (32), Brambilla E (33), Esteller M (34)

    (1) Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, Barcelona, Spain; Department of Respiratory Medicine, Groupement Hospitalier Est, Hôpital Louis-Pradel, Hospices Civils de Lyon, Lyon, France.
    (2) Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, Barcelona, Spain.
    (3) Department of Respiratory Medicine, Groupement Hospitalier Est, Hôpital Louis-Pradel, Hospices Civils de Lyon, Lyon, France.
    (4) Department of Pathology, Centre de biologie et pathologie Est, Institut de Cancérologie des Hospices Civils de Lyon, Université Lyon 1, Lyon, France.
    (5) Department of Respiratory Diseases and Thoracic Oncology, APHP-Hôpital Ambroise Pare, Boulogne-Billancourt, France; EA4340, UVSQ, University Paris-Saclay, Boulogne-Billancourt, France.
    (6) Department of Respiratory Diseases and Thoracic Oncology, APHP-Hôpital Ambroise Pare, Boulogne-Billancourt, France.
    (7) Department of Oncology, University of Turin, AOU San Luigi, Turin, Italy.
    (8) Thoracic Oncology Department, CHU Lille, University of Lille, Lille, France; UMR 8161-M3T-Mechanisms of Tumorigenesis and Targeted Therapies, CNRS, Institut Pasteur de Lille, University of Lille, Lille, France.
    (9) Department of Pathology, CHU Lille, University of Lille, Lille, France.
    (10) Medical Oncology Service, Institute of Oncology Rosell, University Hospital Sagrat Cor, QuironSalud Group, Barcelona, Spain.
    (11) Medical Oncology Service, Quirón Dexeus University Hospital, Barcelona, Catalonia, Spain.
    (12) Medical Oncology Service, University Hospital Sant Joan de Reus, Reus, Spain.
    (13) Program in Solid Tumors and Biomarkers, Center for Applied Medical Research, Pamplona, Spain; Navarra Health Research Institute, Pamplona, Spain; Centro de Investigación Biomédica en Red de Cancer, Madrid, Spain.
    (14) Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; Navarra Health Research Institute, Pamplona, Spain; Centro de Investigación Biomédica en Red de Cancer, Madrid, Spain.
    (15) Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain; Navarra Health Research Institute, Pamplona, Spain.
    (16) Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain; Navarra Health Research Institute, Pamplona, Spain; Centro de Investigación Biomédica en Red de Cancer, Madrid, Spain.
    (17) Pathology Department, University Hospital Bellvitge, Barcelona, Spain.
    (18) Medical Oncology Department, Catalan Institute of Oncology, Hospital Duran I Reynals, Barcelona, Spain.
    (19) Medical Oncology Department, Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Barcelona, Spain.
    (20) Department of Pathology, Hospitales Universitarios Regional y Virgen de la Victoria, Institute of Biomedical Research in Malaga, University of Málaga, Málaga, Spain.
    (21) Medical Oncology Service, Hospitales Universitarios Regional y Virgen de la Victoria, Institute of Biomedical Research in Malaga, University of Málaga, Málaga, Spain.
    (22) Pharmacoepigenetics Group, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
    (23) Cancer Epigenetics Laboratory, Institute of Oncology of Asturias, Hospital Universitario Central de Asturias, Universidad de Oviedo, Oviedo, Spain; Fundación para la Investigación Biosanitaria de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain.
    (24) Nanomaterials & Nanotechnology Research Center, Universidad de Oviedo, Oviedo, Spain.
    (25) CNAG-CRG, Centre for Genomic Regulation, Barcelona Institute of Science and Technology, Barcelona, Spain.
    (26) Pathology Department, Hospital Clinic, Institut d'Investigacions Biomédiques August Pi i Sunyer, Barcelona, Spain.
    (27) Medical Oncology Department, Hospital Clinic, Institut d'Investigacions Biomédiques August Pi i Sunyer, Barcelona, Spain.
    (28) Pathology Department, University Hospital Ramon y Cajal, Madrid, Spain.
    (29) Medical Oncology Service, University Hospital Ramon y Cajal, Madrid, Spain; Centro de Investigación Biomédica en Red de Cancer, Madrid, Spain.
    (30) Medical Oncology Service, Hospitales Universitarios Regional y Virgen de la Victoria, Institute of Biomedical Research in Malaga, University of Málaga, Málaga, Spain; Pharmacoepigenetics Group, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
    (31) Department of Pathology Department, APHP-Hôpital Ambroise Pare, Boulogne-Billancourt, France.
    (32) Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Barcelona, Spain.
    (33) Centre Hospitalier Grenoble, INSERM U1219, University UGA, Grenoble, France.
    (34) Cancer Epigenetics and Biology Program, Bellvitge Biomedical Research Institute, Barcelona, Spain; Centro de Investigación Biomédica en Red de Cancer, Madrid, Spain; Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona, Spain; Institucio Catalana de Recerca i Estudis Avançats, Barcelona, Spain.

    The Lancet. Respiratory Medicine 06 de JULHO de 2019

  • Differences in Venous Thromboembolism Prevention and Outcome between Hospitalized Patients with Solid and Hematologic Malignancies

    Figueroa R (1), Alfonso A (1), Marcos M (1), López-Picazo JM (2), García-Mouriz A (3), Gil-Bazo I (2), Rifón J (1), Hermida J (4,5), Páramo JA (1,5), Lecumberri R (1,5).

    (1) Hematology Service, Clínica Universidad de Navarra, Pamplona, Navarra, Spain.
    (2) Department of Oncology, Clínica Universidad de Navarra, Pamplona, Navarra, Spain.
    (3) Informatics Service, Clínica Universidad de Navarra, Pamplona, Navarra, Spain.
    (4) Center for Applied Medical Research, University of Navarra, Pamplona, Navarra, Spain.
    (5) CIBER-CV, Pamplona, Navarra, Spain.

    TH Open 30 de MAIO de 2019

  • 5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging

    Martínez-Terroba E (1,2), Behrens C (3), Agorreta J (1,2,4,5), Monsó E (6,7), Millares L (6,7), Felip E (8), Rosell R (9), Ramirez JL (9), Remirez A (1), Torre W (4,10), Gil-Bazo I (1,4,5,11), Idoate MA (2,4,5,12), de-Torres JP (4,5,13), Pio R (1,4,5,14), Wistuba II (3,15), Pajares MJ (1,2,4,5), Montuenga LM (1,2,4,5).

    (1) Program in Solid Tumors, CIMA, Pamplona, Spain.
    (2) Department of Pathology, Anatomy and Physiology, School of Medicine, University of Navarra, Pamplona, Spain.
    (3) Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
    (4) Navarra Health Research Institute (IDISNA), Pamplona, Spain.
    (5) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
    (6) Neumology Service, Parc Taulí Universitary Hospital, Sabadell, Spain.
    (7) CIBER de Enfermedades Respiratorias-CIBERES, Instituto de Salud Carlos III, Madrid, Spain.
    (8) Vall d'Hebron University Hospital, Institute of Oncology, Barcelona, Spain.
    (9) Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain.
    (10) Department of Thoracic Surgery, Clínica Universidad de Navarra, Pamplona, Spain.
    (11) Department of Oncology, Clínica Universidad de Navarra, Pamplona, Spain.
    (12) Department of Pathology, Clínica Universidad de Navarra, Pamplona, Spain.
    (13) Department of Neumology, Clínica Universidad de Navarra, Pamplona, Spain.
    (14) Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain.
    (15) Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

    Thorax 01 de ABRIL de 2019

  • The Dynamic Use of EGFR Mutation Analysis in Cell-Free DNA as a Follow-Up Biomarker during Different Treatment Lines in Non-Small-Cell Lung Cancer Patients

    Macías M (1), Alegre E (1,2), Alkorta-Aranburu G (3), Patiño-García A (2,3,4), Mateos B (1), Andueza MP (5), Gúrpide A (2,5), Lopez-Picazo JM (2,5), Gil-Bazo I (2,5,6), Perez-Gracia JL (2,5), González Á (1,2).

    (1) Service of Biochemistry, Clínica Universidad de Navarra, Av. Pio XII 36 Pamplona 31008, Spain.
    (2) Navarra Institute for Health Research (IdiSNA), c/ Irunlarrea 3 31008 Pamplona, Spain.
    (3) Unit of Genomics, CIMA LAB Diagnostics, University of Navarra, Av. Pio XII 55 31008 Pamplona, Spain.
    (4) Department of Pediatrics, Clínica Universidad de Navarra, Av. Pio XII 36 31008 Pamplona, Spain.
    (5) Department of Oncology, Clínica Universidad de Navarra, Av. Pio XII 36 31008 Pamplona, Spain.
    (6) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Av. Monforte de Lemos, 3-5. Pabellón 11. Planta 0 28029 Madrid Madrid, Spain.

    Disease Markers 23 de JANEIRO de 2019

  • Inhibitor of differentiation-1 (Id1) sustains mutant KRAS-driven progression, maintenance, and metastasis of lung adenocarcinoma

    Román M (1), López I (1), Guruceaga E (2), Baraibar I (3), Ecay M (4), Collantes M (4), Nadal E (5), Vallejo A (1), Cadenas S (6), Echávarri-de Miguel M (6), Jang JH (7), San Martín-Uriz P (8), Castro-Labrador L (9), Vilas-Zornoza A (10), Lara-Astiaso D (11), Ponz-Sarvise M (12), Rolfo C (13), Santos ES (14), Raez LE (15), Taverna S (16), Behrens C (17), Weder W (18), Wistuba II (19), Vicent S (20), Gil-Bazo I (21).

    (1) Program of Solid Tumors and Biomarkers, Center for Applied Medical Research.
    (2) Bioinformatics Platform, CIMA, University of Navarra.
    (3) Department of Oncology, Clínica Universidad de Navarra.
    (4) Nuclear Medicine, Clínica Universidad de Navarra.
    (5) Medical Oncology, Catalan Institute of Oncology.
    (6) Program of Solid Tumors, Center for Applied Medical Research.
    (7) Department of Thoracic Surgery, University Hospital of Zurich.
    (8) Program in Solid Tumors and Biomarkers, Center for Applied Medical Research (CIMA).
    (9) Oncohematology, Center for Applied Medical Research (CIMA).
    (10) Advanced Genomics, Center for Applied Medical Research (CIMA).
    (11) Center for Applied Medical Research, Advanced Genomics Laboratory, University of Navarra.
    (12) Medical Oncology, Clinica Universidad de Navarra/Center for Applied Medical Research (CIMA), University of Navarra.
    (13) Thoracic Medical Oncology and Early Clinical Trials, Marlene and Stweart Greenebaum Comprehensive Cancer Center.
    (14) Lynn Cancer Institute.
    (15) Medical Director, Memorial Cancer Institute, Memorial Health Care System.
    (16) Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council.
    (17) Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center.
    (18) Division of Thoracic Surgery, University Hospital Zürich.
    (19) Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center.
    (20) Program of Solid Tumors, Center for Applied Medical Research (CIMA), University of Navarra.
    (21) Department of Oncology, Clínica Universidad de Navarra

    Cancer Research 18 de DEZEMBRO de 2018

talvezlhe interesse

QUE TECNOLOGIA UTILIZAMOS? 

A Clínica é o hospital privado com maiores recursos tecnológicos de Espanha, tudo num único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OS NOSSOS
PROFISSIONAIS

Os profissionais da Clínica realizam um trabalho contínuo de investigação e formação, sempre em benefício do paciente.

Imagen profesionales de la Clínica Universidad de Navarra

RAZÕES PARA VIR
À CLÍNICA

Conheça porque é que somos diferentes em relação a outros centros sanitários. Qualidade, rapidez, comodidade e resultados.

Imagen del edificio de la Clínica Universidad de Navarra